Intracranial hemorrhage (ICH)

Intracranial hemorrhage (ICH) is a pathological condition characterized by bleeding inside the skull, which can occur within the brain parenchyma or the surrounding extra-axial spaces (StatPearls, 2023). It is a life-threatening medical emergency caused by factors such as chronic hypertension, physical trauma, vascular malformations, or the use of anticoagulant medications (Mayo Clinic). Unlike a specific protein receptor or enzyme, ICH represents a clinical syndrome resulting from the loss of vascular structural integrity rather than a discrete molecular target. Pathophysiologically, primary injury is caused by the mechanical compression of brain tissue by the expanding hematoma, while secondary injury arises from subsequent inflammation, oxidative stress, and the neurotoxic effects of blood breakdown products like thrombin and heme (NCBI, PMC9143360). Management strategies focus on achieving hemodynamic stability, reversing coagulopathy, and reducing intracranial pressure using osmotic agents like mannitol or hypertonic saline. While ICH itself is not a molecular target, it serves as a critical therapeutic indication for various drugs targeting the coagulation cascade and neuroprotective pathways.

Other names

Cerebral hemorrhageBrain bleedHemorrhagic strokeIntraparenchymal hemorrhageSubarachnoid hemorrhageSubdural hematomaEpidural hematoma

Management involves the osmotic reduction of intracranial pressure, pharmacological reversal of systemic anticoagulation to limit hematoma expansion, stabilization of the blood-brain barrier, and inhibition of fibrinolysis to promote hemostasis.